

October 6th, 2025

***Business in Vancouver* Shines a Spotlight on Acuitas Therapeutics in its Life Sciences 2025 Feature**

Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems, has been featured in the prestigious *Business in Vancouver* Life Sciences 2025 magazine.

The article, written by Acuitas CEO Dr. Thomas Madden, is entitled “Shaping the Future of Gene Editing Here at Home in B.C.” and it highlights how Acuitas-developed LNP technologies have enabled groundbreaking advances in gene editing, and explores their potential to improve patient outcomes worldwide. It also celebrates innovation across B.C.’s life sciences ecosystem and the province’s potential to grow into a global scientific hub.

The full article can be found [here](#) on page 33.

About Acuitas Therapeutics

Acuitas Therapeutics, Inc. is a Vancouver-based company focused on developing and optimizing lipid nanoparticle (LNP) delivery systems for nucleic acid-based therapeutics. They collaborate with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas’ clinically validated LNP technology has had a profound global impact – most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. The technology also enables **ONPATTRO®** by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and *in vivo* CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases – such as malaria, HIV/AIDS, and tuberculosis – as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit www.acuitastx.com.

-END-

Media Contact:

Ruth Atherley

ratherley@acuitastx.com